Prix Galien USA Awards Committee members and invited experts will chair three webinars highlighting each of the 25 nominated products in the Best Biotechnology Product category. 

These virtual panel exchanges will offer the opportunity for webinar participants to assess the current state of innovation in branded biotechnology products, covering key aspects of clinical progress and therapeutic differentiation; new access challenges, especially in a changing US market characterized, for the first time, by public price negotiations; and upcoming developments in next-generation technology platforms, drugs and vaccines. 

Top of mind will be the transformative – and possibly disruptive – effects of this new science on health system productivity and patient outcomes worldwide. 

In an panel with the eight nominees for the “Best Product for Rare/Orphan Diseases” Award, this virtual exchange will offer the opportunity for webinar participants to assess the current state of innovation in the branded rare and orphan disease space.

The discussion will cover key aspects of clinical progress. This virtual exchange will offer the opportunity for webinar participants to assess the current state of innovation in branded rare and orphan disease products, covering key aspects of clinical progress and therapeutic differentiation; new access challenges, especially involving novel pricing for medicines with high price tags for small populations; and the latest developments in next-generation technology platforms and personalized treatments based on extensive mapping of individual DNA and cell structures.

Top of mind will be the transformative – and possibly disruptive – effects of this new science on health system productivity and patient outcomes worldwide. 

The Prix Galien USA Awards Committee and invited experts will chair three webinars highlighting each of the 29 nominated products in the Best Medical Technology Category. 

These virtual panel exchanges will offer the opportunity for webinar participants to assess the current state of innovation in branded medical technology devices and diagnostics, covering key aspects of clinical progress and therapeutic differentiation as well as new access challenges as the US institutional health infrastructure confronts significant budgetary constraints. 

Top of mind will be the transformative - and possibly disruptive - effects of new technologies like AI on health system productivity and patient outcomes worldwide. 

Building on the demand for remote technology applications during the Covid-19 pandemic, digital health is enabling a realignment of health provision around integrative disease management combined with personalized wellness solutions – goals that will hopefully secure better outcomes for patients.

With rising levels of real-time and actionable data, backers of digital health also promise lower costs per episode of care as well as helping regulation and clinical management protocols become more targeted and efficient.

Of course, none of these transformative gains would be possible without this community of digital innovators, whose impact is registered by the 21 software apps and platforms, devices and diagnostics the Prix Galien USA Awards Committee has nominated for 2024’s “best in class” – double the number from last year.

Incubator and accelerators are pivotal in developing innovative solutions to addressing humanity’s most pressing health care challenges. 

Why are academic institutes, major medical centers/hospitals, and the top 10 pharma companies launching incubators and accelerator ventures to offer guidance to biotech, digital health, health information, and medical device start-ups, often under their own umbrella? 

Beyond financial and intellectual resources, how are these groups working to advance ideas into the marketplace, and what is their actual clinical impact?